---
title: "Obefazimod (ABX464) in Ulcerative colitis: Thiopurines and methotrexate"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Thiopurines and methotrexate. Topics: Recommendations for thiopurines and methotrexate: ACG 2025 guideline, Efficacy of thiopurines and methotrexate: ACG 2025 guideline, Recommendations for immunomodulator monotherapy and combination therapy: AGA 2024 living guideline, Efficacy and harms of thiopurines and combination therapy: AGA 2024 living guideline, and 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/thiopurines-and-methotrexate"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Thiopurines and methotrexate

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Thiopurines and Methotrexate

<a id="topic-2.2.2.1.3-1"></a>

### Recommendations for thiopurines and methotrexate: ACG 2025 guideline

> “23. In patients with moderately to severely active UC, we recommend against monotherapy with thiopurines or methotrexate for induction of remission (Strong recommendation, low quality of evidence).”
> “33. When infliximab is used as induction therapy for patients with moderately to severely active UC, we recommend combination therapy with a thiopurine (Strong recommendation, moderate quality of evidence for azathioprine).”
> “36. For patients with prior moderately to severely active UC now in remission because of corticosteroid induction, we suggest thiopurines for maintenance of remission as compared with no treatment or corticosteroids (Conditional recommendation, low quality of evidence).”
> “37. In patients with prior moderately to severely active UC now in remission, we suggest against using methotrexate for maintenance of remission (Conditional recommendation, low quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.3-2"></a>

### Efficacy of thiopurines and methotrexate: ACG 2025 guideline

> “Thiopurines are slow-acting and do not induce remission in moderately to severely active UC (164–166). Similarly, methotrexate is not an effective induction agent in moderately to severely active UC.”
> “In an additional 3 RCTs, azathioprine prevented relapse in 127 patients (RR = 0.6; 95% CI 0.37–0.95) (165).”
> “When compared with placebo, treatment with thiopurines resulted in an absolute risk reduction of 23% and an NNT of 5 to prevent recurrence (OR = 2.59; 95% CI 1.26–5.3) (169).”
> “In this study, 29/44 (66%) patients receiving methotrexate experienced relapse compared with 25/40 (63%) patients receiving placebo (172).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.3-3"></a>

### Recommendations for immunomodulator monotherapy and combination therapy: AGA 2024 living guideline

> “5. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using thiopurine monotherapy for induction of remission. [Conditional recommendation, very low certainty of evidence]”
> “6. In adult outpatients with moderate-to-severe UC in remission, the AGA suggests using thiopurine monotherapy, rather than no treatment, for maintenance of remission, typically induced by corticosteroids. [Conditional recommendation, low certainty of evidence]”
> “7. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using methotrexate monotherapy, for induction or maintenance of remission. [Conditional recommendation, low certainty of evidence]”
> “8. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab in combination with an immunomodulator over infliximab or an immunomodulator alone. [Conditional recommendation, moderate certainty of evidence]”
> “9. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of adalimumab or golimumab in combination with an immunomodulator over adalimumab, golimumab or immunomodulator monotherapy. [Conditional recommendation, low certainty of evidence]”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.3-4"></a>

### Efficacy and harms of thiopurines and combination therapy: AGA 2024 living guideline

> “On meta-analysis, thiopurines were more effective than placebo or 5-ASA for decreasing risk of disease relapse (RR, 0.61; 95% CI, 0.49–0.77) among patients with inactive UC (in remission) (eFigure 14).”
> “At week 16, the primary endpoint of corticosteroid-free clinical remission was achieved by 39.7% of patients receiving combination therapy compared to 22.1% of infliximab treated patients and 23.7% of azathioprine treated patients.”
> “Short- and long-term side effects of thiopurines and methotrexate are well-recognized including risk of bone marrow suppression, hepatotoxicity (including liver fibrosis with long-term use of methotrexate), non-melanoma skin cancer and lymphoma, especially with thiopurines78.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.3-5"></a>

### Recommendations for thiopurines: ECCO 2026 guideline

> “We recommend against the use of thiopurines as monotherapy for the induction of remission in patients with active ulcerative colitis [strong recommendation, very low certainty of evidence] [Agreement: 100%]”
> “We suggest monotherapy with thiopurines for the maintenance of remission in patients under 65 years of age with steroid-dependent ulcerative colitis or who are intolerant to 5-aminosalicylates [weak recommendation, low certainty of evidence] [Agreement: 98%]”
> “In 232 patients followed for 1 year, azathioprine was superior to placebo for the maintenance of clinical remission [RR: 1.59; 95% CI: 1.19–2.11].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.3-6"></a>

### Boxed warning for azathioprine

> “Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease.”

Source: [Imuran prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016324s040lbl.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
